{"schema":"sb.node.v1","id":"sb:e/202787c96a0ef87cc692bb67","kind":"entity","label":{"text":"braf","locale":"en"},"identity":{"anchor":"label:en:braf","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T23:32:17.032179+00:00","snapshot":"deploy 30eccbd0a92992f24ee73467899162618bbca4e7"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":123,"separatePublishers":53,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-15","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.114: about 89% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","pubmed_targeted","precision_medicine"],"activeDays":80,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/87972f89a9ad612147f5e4f1","kind":"observation","label":"Frontiers Precision Oncology · 2026-10-02 · Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1967814"},{"id":"sb:o/1af8d23d18fa643342465611","kind":"observation","label":"Colorectal Dis · 2026-10-01 · Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study.","url":"https://doi.org/10.1111/codi.70639"},{"id":"sb:o/6b73edeb420631e7d840ef17","kind":"observation","label":"Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r…","url":"https://doi.org/10.1097/CAD.0000000000001846"},{"id":"sb:o/4206bfc0206843f420ccccf5","kind":"observation","label":"The ASCO Post · 2026-09-22 · BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows","url":"https://ascopost.com/news/september-2026/braf-class-alterations-in-nsclc-have-different-characteristics-outcomes-and-co-mutations-research-shows/"},{"id":"sb:o/8ac522b1dc17f981ab2812d5","kind":"observation","label":"Inside Precision Medicine · 2026-09-15 · BRAF Mutation Class Influences Outcomes in NSCLC","url":"https://www.insideprecisionmedicine.com/topics/oncology/braf-mutation-class-influences-outcomes-in-nsclc/"},{"id":"sb:o/546f3402510ae50ce6bca311","kind":"observation","label":"Journal of Clinical Oncology · 2026-09-13 · Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of t…","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00355?af=R"},{"id":"sb:o/e50f170205583c9ffce26409","kind":"observation","label":"Annals of Oncology · 2026-09-13 · A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3","url":"https://www.sciencedirect.com/science/article/pii/S0923753426001791?dgcid=rss_sd_all"},{"id":"sb:o/01857dacc166c0f06f83d15a","kind":"observation","label":"Clinical Colorectal Cancer · 2026-09-11 · Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A …","url":"https://www.sciencedirect.com/science/article/pii/S1533002826000046?dgcid=rss_sd_all"},{"id":"sb:o/3ef642698a6c25e4c929c63f","kind":"observation","label":"J Dermatol · 2026-09-04 · Eruptive Melanocytic Nevi Associated With Encorafenib and Cetuximab Therapy in Two Patients With BRAF V600E-Mutated Colorectal Cancer.","url":"https://doi.org/10.1111/1346-8138.70488"},{"id":"sb:o/25a74a90ffc211df49d8bc71","kind":"observation","label":"crc-digest · 2026-09-03 · Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC","url":"https://www.sciencedirect.com/science/article/pii/S1533002826000678?dgcid=rss_sd_all"}],"cursor":"c1.eyJpZCI6InNiOmUvMjAyNzg3Yzk2YTBlZjg3Y2M2OTJiYjY3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIzOjMyOjE3LjAzMjE3OSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with colorectal cancer (85 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b84af19e783646a35cc61af0"},{"kind":"relation","label":"co-mentioned with braf v600e (41 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/593e374e4f97be70e14a0a5b"},{"kind":"relation","label":"co-mentioned with egfr (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/38b901852a2dcf6c11b4b942"},{"kind":"relation","label":"co-mentioned with kras (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/abaa7c6a30c041e79af1c7de"},{"kind":"relation","label":"co-mentioned with immunotherapy (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/34e15dd5645196cae5210f56"},{"kind":"relation","label":"co-mentioned with ai (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/02438ab316cc35ab12fadcbe"},{"kind":"relation","label":"co-mentioned with ctdna (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5a7cdf1c2c3a35437cee0bb7"},{"kind":"relation","label":"co-mentioned with her2 (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2b0cb79abc851a45bee51b76"},{"kind":"relation","label":"co-mentioned with lung cancer (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5b39a67780bcbea14b65ea05"},{"kind":"relation","label":"co-mentioned with creative commons (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fa17f52c9fe2b85f7fd69c5e"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/202787c96a0ef87cc692bb67","mcp":"traverse {\"id\":\"sb:e/202787c96a0ef87cc692bb67\"}","page":"/entity/braf/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/202787c96a0ef87cc692bb67\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/202787c96a0ef87cc692bb67\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/202787c96a0ef87cc692bb67\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/202787c96a0ef87cc692bb67\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}